$MBRX News

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial Evaluating Annamycin In R/R AML During Investor Segment

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

Why is Moleculin Stock Falling Today?

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With Cytarabine

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Moleculin Biotech Announces Publication Of An Abstract At The European Hematology Association Congress That Highlights The Cardiac Safety Profile Of Annamycin